Resources>Blog>Top 10 Antibody Drug Approvals from FDA 2023

Top 10 Antibody Drug Approvals from FDA 2023

Biointron 2024-01-20 Read time: 3 mins
FDA.jpg
Image credit: Adobe Stock

Antibodies are an essential part of our immune system, and over the years, scientists have developed a range of antibody-based drugs that are used to treat various diseases. In recent years, many antibody drugs have received approval from the US Food and Drug Administration (FDA) for their safety and effectiveness. Here are the top 10 antibody drugs approved by the FDA:

  1. Humira (adalimumab): This antibody drug is used to treat a range of autoimmune diseases, including rheumatoid arthritis and psoriasis.

  2. Rituxan (rituximab): This antibody drug is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.

  3. Avastin (bevacizumab): This antibody drug is used to treat certain types of cancer, including colon, lung, and brain cancer.

  4. Herceptin (trastuzumab): This antibody drug is used to treat HER2-positive breast cancer.

  5. Remicade (infliximab): This antibody drug is used to treat autoimmune diseases, including Crohn's disease and rheumatoid arthritis.

  6. Keytruda (pembrolizumab): This antibody drug is used to treat various types of cancer, including melanoma, lung cancer, and head and neck cancer.

  7. Opdivo (nivolumab): This antibody drug is used to treat various types of cancer, including melanoma, lung cancer, and kidney cancer.

  8. Erbitux (cetuximab): This antibody drug is used to treat colon cancer and head and neck cancer.

  9. Prolia (denosumab): This antibody drug is used to treat osteoporosis.

  10. Xolair (omalizumab): This antibody drug is used to treat asthma and allergic rhinitis.

At Biointron, we offer high-quality recombinant antibody production services that can help researchers and biotech companies develop antibody-based drugs for various diseases. Our team of experts can provide customized solutions that meet your specific research needs. Contact us to learn more about our services and how we can help accelerate your research and drug development projects.

Subscribe to our Blog
Recommended Articles
Next-Generation Antibody Conjugates for Targeted Anticancer Drug Delivery

In this article, we explore the major trends shaping the future of targeted canc……

May 29, 2026
Site-Specific Conjugation Strategies for Next-Generation Antibody-Drug Conjugates

Site-specific conjugation limits payload attachment to defined positions on the ……

May 27, 2026
How Surface Patches Shape Antibody Specificity and Developability

Affinity maturation can improve binding to the intended target, but it can also ……

May 25, 2026
XDCs: The Evolution of Antibody-Drug Conjugates

ADC development is no longer limited to the antibody-linker-toxin model. The fie……

May 23, 2026

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.